In this study, we generated new in-vivo treatment models of Brca1- and Bard1-mutant breast cancer that recapitulate the striking response to PARPi, acquired resistance, and recurrence that is observed in patients with breast cancer. The gene discussed is BARD1; the disease is breast carcinoma.